Cefalexin (cephalexin) is a commonly prescribed antibiotic in the UK, and many patients with fatty liver disease wonder whether it is safe to take. The reassuring news is that cefalexin is generally considered safe for people with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD). Unlike some antibiotics that undergo extensive liver metabolism, cefalexin is primarily eliminated by the kidneys, with approximately 90% excreted unchanged in urine. This article explains how cefalexin works, its safety profile in fatty liver disease, and when to seek medical advice.

What Is Cefalexin and How Does It Work?

Cefalexin (also known as cephalexin) is a first-generation cephalosporin antibiotic used in the UK to treat bacterial infections. It belongs to the beta-lactam family of antibiotics and works by interfering with bacterial cell wall synthesis, ultimately causing bacterial cell death. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved cefalexin for various indications, and it is prescribed in primary care when clinically appropriate.

This antibiotic is particularly effective against Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pyogenes, as well as some Gram-negative organisms. Common conditions treated with cefalexin include:

• Skin and soft tissue infections (cellulitis, abscesses, wound infections)

• Respiratory tract infections (when indicated by local antimicrobial guidelines and susceptibility)

• Urinary tract infections (typically when first-line options are unsuitable)

• Bone and joint infections (usually under specialist guidance)

• Otitis media (middle ear infections)

Cefalexin is typically administered orally in capsule or liquid suspension form. According to the British National Formulary (BNF), standard adult doses range from 250 mg to 500 mg taken two to four times daily, with a maximum of 4 g daily in divided doses, depending on the severity and type of infection. The medication is generally well-absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 60 minutes of oral administration. Dose adjustment is required in renal impairment; your prescriber will assess kidney function if necessary.

Metabolism and elimination of cefalexin occur primarily through the kidneys, with approximately 90% of the drug excreted unchanged in urine within eight hours. This renal elimination pathway is particularly relevant when considering drug safety in patients with various medical conditions, including liver disease. Unlike some antibiotics that undergo extensive hepatic metabolism, cefalexin's minimal liver processing means it does not typically require dose adjustment in hepatic impairment alone. Selection of cefalexin should follow local antimicrobial prescribing guidelines and, where appropriate, culture and susceptibility results to support antimicrobial stewardship.

Understanding Fatty Liver Disease and Medication Safety

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. In the UK, this condition is estimated to affect a substantial proportion of the general population and is increasingly recognised as a significant public health concern. The condition exists in two main forms: non-alcoholic fatty liver disease (NAFLD), which is unrelated to alcohol consumption, and alcoholic fatty liver disease (AFLD), which results from excessive alcohol intake. (Note: the term metabolic dysfunction-associated steatotic liver disease (MASLD) is now emerging in clinical practice, though NAFLD remains widely used in the UK.)

NAFLD has become one of the most common chronic liver conditions in the UK, closely associated with obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease. The spectrum of NAFLD ranges from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and potential progression to fibrosis, cirrhosis, or hepatocellular carcinoma.

Medication safety in fatty liver disease requires careful consideration because the liver plays a central role in drug metabolism. Patients with hepatic steatosis may have:

• Altered drug metabolism and clearance

• Increased susceptibility to drug-induced liver injury

• Reduced capacity to process medications that undergo hepatic biotransformation

• Potential for drug accumulation if liver function is significantly impaired

Clinicians should consider hepatic function when prescribing medications known to be hepatotoxic or extensively metabolised by the liver. However, the degree of concern varies considerably depending on the specific medication's metabolic pathway. Drugs primarily eliminated by the kidneys generally pose less risk to patients with fatty liver disease, provided renal function remains normal. According to NICE guideline NG49, patients with NAFLD should be assessed for risk of advanced fibrosis using validated scores such as the FIB-4 or NAFLD fibrosis score, with monitoring intervals based on individual risk stratification. Understanding these principles helps clinicians make informed prescribing decisions whilst balancing the need to treat infections effectively against potential risks to liver health.

Can You Take Cefalexin If You Have Fatty Liver Disease?

The reassuring news is that cefalexin is generally considered safe for patients with fatty liver disease, including both NAFLD and compensated liver disease. This safety profile stems primarily from cefalexin's pharmacokinetic properties—specifically, its predominantly renal elimination pathway with minimal hepatic metabolism. There is no contraindication to using cefalexin in patients with fatty liver disease according to the British National Formulary (BNF) and the MHRA Summary of Product Characteristics (SmPC) for cefalexin.

Unlike antibiotics such as erythromycin, co-amoxiclav, or flucloxacillin—which undergo significant liver metabolism and carry recognised hepatotoxicity risks—cefalexin passes through the liver largely unchanged. Approximately 90% of cefalexin is excreted unchanged by the kidneys, meaning the liver's metabolic capacity has minimal impact on drug clearance in most patients. This makes cefalexin a reasonable option when treating bacterial infections in individuals with known hepatic steatosis, provided it is clinically indicated.

However, several important considerations apply:

• Patients with advanced liver disease (cirrhosis, decompensated liver function) require more careful assessment

• Dose adjustments are typically unnecessary for fatty liver disease alone, but are required if concurrent renal impairment exists (consult the BNF for renal dosing)

• The underlying infection being treated must warrant antibiotic therapy—cefalexin should only be prescribed for confirmed or strongly suspected bacterial infections, following local antimicrobial guidelines and, where appropriate, culture and susceptibility results

• Individual patient factors, including other medications (e.g., cefalexin may enhance the anticoagulant effect of warfarin; INR monitoring is advised) and comorbidities, should be considered

Clinical practice in the UK generally supports the use of cefalexin in patients with fatty liver disease when clinically indicated. Your GP or prescribing clinician will assess your overall health status, including liver function tests if available, to ensure cefalexin is appropriate for your specific situation. If you have concerns about taking cefalexin with fatty liver disease, discuss these with your healthcare provider, who can provide personalised advice based on your medical history.

Monitoring Liver Function When Taking Cefalexin

Routine liver function monitoring is not typically required for patients taking cefalexin, even in those with pre-existing fatty liver disease. This differs from antibiotics with known hepatotoxic potential, where regular blood tests may be recommended. The low risk of liver injury with cefalexin means that most patients can complete their antibiotic course without specific hepatic monitoring.

However, baseline liver function tests (LFTs) may already be part of your medical records if you have diagnosed fatty liver disease. These typically include:

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)—enzymes that indicate liver cell damage

• Alkaline phosphatase (ALP)—elevated in bile duct problems

• Bilirubin—a marker of the liver's processing capacity

• Albumin—reflects the liver's synthetic function

• Gamma-glutamyl transferase (GGT)—sensitive to liver and bile duct disease

If you have established fatty liver disease, your GP will assess your risk of advanced fibrosis using validated scores such as the FIB-4 or NAFLD fibrosis score, as recommended by NICE guideline NG49. Monitoring intervals are then based on your individual risk stratification, rather than routine annual blood tests for all patients. Taking a short course of cefalexin does not usually necessitate additional testing beyond this standard monitoring schedule.

Situations where monitoring might be considered include:

• Prolonged courses of cefalexin (beyond 2–3 weeks)

• Patients with advanced liver disease or cirrhosis

• Development of symptoms suggesting liver dysfunction during treatment

• Concurrent use of other potentially hepatotoxic medications

Most cefalexin prescriptions in primary care are for 7–14 day courses, which pose minimal risk even to patients with fatty liver disease. Important safety note: whilst taking cefalexin, be alert for signs of serious adverse effects. If you develop severe or persistent diarrhoea (which may be watery or bloody), stop the antibiotic and contact your GP urgently, as this may indicate Clostridioides difficile infection. If you experience symptoms of a severe allergic reaction—such as facial or tongue swelling, difficulty breathing, or widespread hives—call 999 or go to A&E immediately. If you develop unusual symptoms such as jaundice (yellowing of skin or eyes), dark urine, pale stools, or unexplained fatigue, contact your GP promptly, as these could indicate liver problems, though such reactions to cefalexin are exceptionally rare.

When to Seek Medical Advice About Cefalexin and Liver Health

Immediate medical attention is warranted if you develop certain symptoms whilst taking cefalexin, particularly if you have underlying fatty liver disease. Whilst serious liver reactions to cefalexin are extremely uncommon, being aware of warning signs ensures prompt intervention if problems arise.

Call 999 or go to A&E immediately if you experience:

• Severe allergic reaction (anaphylaxis)—facial or tongue swelling, difficulty breathing, widespread hives, or feeling faint

Stop taking cefalexin and contact your GP urgently or seek same-day medical advice if you experience:

• Severe, persistent, or bloody diarrhoea, which may indicate Clostridioides difficile infection

• Jaundice—yellowing of the skin or whites of the eyes

• Dark urine (tea-coloured) combined with pale or clay-coloured stools

• Severe abdominal pain, particularly in the upper right quadrant

• Unexplained nausea, vomiting, or loss of appetite that is persistent

• Unusual bruising or bleeding, which may indicate impaired liver function

• Severe fatigue or confusion (in people with advanced liver disease, this may suggest worsening hepatic function)

Before starting cefalexin, inform your prescriber if you:

• Have diagnosed fatty liver disease, cirrhosis, or any chronic liver condition

• Have previously experienced liver problems with antibiotics

• Are taking other medications that affect the liver or interact with cefalexin (e.g., warfarin, which may require INR monitoring)

• Have kidney disease (as dose adjustment may be necessary)

• Have a history of allergic reactions to penicillins or cephalosporins

Routine follow-up with your GP is appropriate if you have fatty liver disease and have completed a course of cefalexin without incident. Your regular liver disease monitoring schedule, based on NICE NG49 risk stratification (using FIB-4 or NAFLD fibrosis score), should continue as planned. If your infection does not improve after 2–3 days of cefalexin therapy, contact your prescriber, as this may indicate antibiotic resistance or a non-bacterial cause requiring alternative treatment.

For ongoing liver health management, NICE recommends that patients with NAFLD receive regular risk assessment, lifestyle modification advice (weight loss, exercise, dietary changes), and management of associated conditions such as diabetes and hyperlipidaemia. Taking cefalexin when medically necessary should not interfere with these long-term management strategies. Always maintain open communication with your healthcare team about all medications you take and any concerns about your liver health.

Reporting side effects: If you experience any side effects whilst taking cefalexin, you can report them via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or by using the Yellow Card app. This helps improve the safety of medicines for everyone.

Frequently Asked Questions